Why were there reported cases of people still getting exposed to COVID and dying from it despite having taken the vaccines? Biden himself got infected last year despite having been jabbed multiple times. I thought they were supposed to stop COVID?

As I’m sure you’re aware by now, the spike protein producing therapeutic injections, though we were all told by many high level leaders that it would halt Covid in its tracks, did nothing of the kind. Even the moving goalpost statements that it would first protect from infection and transmission, then only infection, then severe infection, then hospitalisation and death, were a gross overestimation of their capabilities.

A lot of pro-advocates repeatedly state “they were never meant to prevent infection, just to give your immune system a ‘look’ at the virus to help it combat it” but even that has fallen by the wayside. Why? Immunological Imprinting. By the way, when you hear that line, know that there is no mechanism in nature that allows infection of a pathogen but miraculously protects you from the effects of it once it is infecting you. The only thing that is happening is the toleration of the virus.

In the beginning, when the orignal WH1 (Wuhan) strain was circulating (though it never made it out of Asia), people might have gained some benefit from the spike they were manufacturing themselves, but due to the nature of the viral glycoprotein and the plasticity (mutational) capacity, the spike evolved to evade the antibodies created

[1]. Successive injections, showing the body the same spike configuration when the wild virus had already mutated, created an immune selection pressure to allow further escape from any cross neutralising antibodies

[2]. Hence why, as the variants advanced, the transmissibility was improved and the virulence lessened. People’s immune responses only began creating antibodies in greater titres to the original strain that went extinct in 2020, not the variants.

Repeated boosting then lowers the humoral response into toleration mode, as shown here:Extended SARS-CoV-2 RBD booster vaccination induces humoral and cellular immune tolerance in miceThe repetitive applications of vaccine boosters have been brought up in face of continuous emergence of SARS-CoV-2 variants with neutralization escape…https://www.sciencedirect.com/science/article/pii/S2589004222017515

And in these studies showing the switch to IgG4 class which has the effect of only suppressing symptoms, not clearing the virus upon rechallenge:

Class switch towards non-inflammatory IgG isotypes after repeated SARS-CoV-2 mRNA vaccination Class switch towards non-inflammatory IgG isotypes after repeated SARS-CoV-2 mRNA vaccination Published https://www.science.org/doi/10.1126/sciimmunol.ade2798

mRNA vaccines against SARS-CoV-2 induce comparably low long-term IgG Fc galactosylation and sialylation levels but increasing long-term IgG4 responses compared to an adenovirus-based vaccine mRNA vaccines against SARS-CoV-2 induce comparably low long-term IgG Fc galactosylation and sialylation levels but increasing long-term IgG4 responses compared to an adenovirus-based vaccine

IgG4 Antibodies Induced by mRNA Vaccines Generate Immune Tolerance to SARS-CoV-2’spike Protein by Suppressing the Immune System IgG4 Antibodies Induced by mRNA Vaccines Generate Immune Tolerance to SARS-CoV-2’spike Protein by Suppressing the Immune System

You can read more about this here:Deep immunological imprinting due to the ancestral spike in the current bivalent COVID-19 vaccine

With the aim of broadening immune responses against the evolving SARS-CoV-2 Omicron variants, bivalent COVID-19 mRNA vaccines that encode the ancestral and Omicron BA.5 spike proteins have been authorized for clinical use, supplanting the original monovalent counterpart in numerous countries. However, recent studies have demonstrated that administering either a monovalent or bivalent vaccine as a fourth vaccine dose results in similar neutralizing antibody titers against the latest Omicron subvariants, raising the possibility of immunological imprinting. Utilizing binding immunoassays, pseudotyped virus neutralization assays, and antigenic mapping, we investigated antibody responses from 72 participants who received three monovalent mRNA vaccine doses followed by either a bivalent or monovalent booster, or who experienced breakthrough infections with the BA.5 or BQ subvariant after vaccinations with an original monovalent vaccine. Compared to a monovalent booster, the bivalent booster did not yield noticeably higher binding titers to D614G, BA.5, and BQ.1.1 spike proteins, nor higher virus-neutralizing titers against SARS-CoV-2 variants including the predominant XBB.1.5 and the emergent XBB.1.16. However, sera from breakthrough infection cohorts neutralized Omicron subvariants significantly better. Multiple analyses of these results, including antigenic mapping, made clear that inclusion of the ancestral spike prevents the broadening of antibodies to the BA.5 component in the bivalent vaccine, thereby defeating its intended goal. Our findings suggest that the ancestral spike in the current bivalent COVID-19 vaccine is the cause of deep immunological imprinting. Its removal from future vaccine compositions is therefore strongly recommended. ### Competing Interest Statement The authors declare potential conflicts of interest as follows: D.D.H. is a co-founder of TaiMed Biologics and RenBio, as well as a board director for Vicarious Surgical; he also serves as a consultant to WuXi Biologics, Brii Biosciences, and Veru; and he receives research support from Regeneron. A.G. served on a scientific advisory board for Janssen Pharmaceuticals. The remaining authors declare no competing interests. https://www.biorxiv.org/content/10.1101/2023.05.03.539268v1

The boosters have been observed to generate stronger responses to the original strain rather than the circulating variants (though the variants in the booster were obselete by the time they hit the market):

Immunogenicity of BA.5 Bivalent mRNA Vaccine Boostershttps://www.nejm.org/doi/full/10.1056/NEJMc2213948

Authors note:

Our data indicate that both monovalent and bivalent mRNA boosters markedly increased antibody responses but did not substantially augment T-cell responses. Neutralizing antibody titers against the ancestral strain of SARS-CoV-2 were higher than titers against BA.5 after both monovalent and bivalent boosting. The median BA.5 neutralizing antibody titer was similar after monovalent and bivalent mRNA boosting, with a modest trend favoring the bivalent booster by a factor of 1.3. It is possible that larger studies may show a greater between-group difference, but any such comparative studies between monovalent and bivalent mRNA boosters would need to enroll the two cohorts within the same time frame and after the BA.5 surge, because negative results on nucleocapsid serologic analysis would not exclude all infected participants. These data are consistent with the modest benefits observed with a BA.1-containing bivalent mRNA booster.4 Our findings suggest that immune imprinting by previous antigenic exposure5 may pose a greater challenge than is currently appreciated for inducing robust immunity against SARS-CoV-2 variants.

And here:

Antibody responses to Omicron BA.4/BA.5 bivalent mRNA vaccine booster shot Antibody responses to Omicron BA.4/BA.5 bivalent mRNA vaccine booster shot

Boosting with a new bivalent mRNA vaccine targeting both BA.4/BA.5 and an ancestral SARS-CoV-2 strain did not elicit a discernibly superior virus-neutralizing antibody responses compared boosting with an original monovalent vaccine. These findings may be indicative of immunological imprinting5, although follow-up studies are needed to determine if the antibody responses will deviate in time, including the impact of a second bivalent booster.

This one might interest you as well:

Immunogenicity of the BA.1 and BA.4/BA.5 SARS-CoV-2 Bivalent Boosts: Preliminary Results from the COVAIL Randomized Clinical Trial Immunogenicity of the BA.1 and BA.4/BA.5 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Bivalent Boosts: Preliminary Results From the COVAIL Randomized Clinical Trial

Titers against BQ.1.1 and XBB.1 were 8-22 times and 13-35 times lower than against BA.1 and D614G, respectively, with the Wildtype/Omicron BA.1 vaccine. Titers against BQ.1.1 and XBB.1 were 4-12 times and 8-22 times lower than against BA.4/BA.5 and D614G, respectively, with the Wildtype/Omicron BA.4/BA.5 vaccine. However, there was increasing neutralization escape with the late 2022 Omicron subvariants (BQ.1.1 and XBB.1). This escape is similar between the two bivalent vaccines as demonstrated by numerically similar GMTs with overlapping confidence intervals, even though BA.1 and BA.4/BA.5 spike sequences are known to have different mutations in the receptor binding domain.7 Our findings highlight ongoing concern that the breadth of antibody response from current updated vaccines is not optimal for the pace of virus evolution.

The recently published Cleveland Clinic study …Effectiveness of the Coronavirus Disease 2019 (COVID-19) Bivalent VaccineAmong 51017 working-aged Cleveland Clinic employees, the bivalent COVID-19 vaccine was 29% effective in preventing infection while the BA.4/5 lineages were domihttps://academic.oup.com/ofid/advance-article/doi/10.1093/ofid/ofad209/7131292?login=false

… shows this repeated infection scenario.

So is it any wonder why the Icelandic study; Rate of SARS-CoV-2 Reinfection During an Omicron Wave in Iceland; showed a higher probability of reinfection the more jabs received?

In this population-based cohort study, a substantial proportion of persons experienced SARS-CoV-2 reinfection during the first 74 days of the Omicron wave in Iceland, with rates as high 15.1% among those aged 18 to 29 years. Longer time from initial infection was associated with a higher probability of reinfection, although the difference was smaller than expected. Surprisingly, 2 or more doses of vaccine were associated with a slightly higher probability of reinfection compared with 1 dose or less.’

Hope that answers your question. Feel free to follow our Space to keep up to date with pandemic news.

[1]

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4248992/

[2]

Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution – Nature